We are live on ! Find out more
GYRE icon

Gyre Therapeutics
GYRE

78 hedge funds and large institutions have $56.5M invested in Gyre Therapeutics in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,625% more call options, than puts

Call options by funds: $309K | Put options by funds: $4K

65% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 20

0.1% more ownership

Funds ownership: 8.42% → 8.52% (+0.1%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less funds holding

Funds holding: 79 → 78 (-1)

10% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 10

31% less capital invested

Capital invested by funds: $81.8M → $56.5M (-$25.2M)

Holders
78
Holders Change
-1
Holders Change %
-1.27%
% of All Funds
1.57%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
33
Reduced
20
Closed
10
Calls
$309K
Puts
$4K
Net Calls
+$305K
Net Calls Change
-$26K

Top Buyers

1
SCM
Stonepine Capital Management
Oregon
+$4.51M
2
BlackRock
BlackRock
New York
+$994K
3
Renaissance Technologies
Renaissance Technologies
New York
+$878K
4
Goldman Sachs
Goldman Sachs
New York
+$546K
5
PM
Prosight Management
Texas
+$280K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$2M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.28M
3
CCM
CAAS Capital Management
New York
-$1.05M
4
Millennium Management
Millennium Management
New York
-$1.01M
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$888K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$7.83M – – –
ACP
2
Acuta Capital Partners
California
$6.44M – – –
SCM
3
Stonepine Capital Management
Oregon
$6.07M +$4.51M +115,183 +158%
BlackRock
4
BlackRock
New York
$5.49M +$994K +25,403 +18%
Vanguard Group
5
Vanguard Group
Pennsylvania
$3.95M -$92K -2,351 -2%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$3.35M +$108K +2,765 +3%
2L
7
22NW LP
Washington
$3.32M +$190K +4,863 +5%
Two Sigma Investments
8
Two Sigma Investments
New York
$1.5M +$157K +4,008 +9%
Northern Trust
9
Northern Trust
Illinois
$1.4M +$189K +4,833 +13%
PM
10
Prosight Management
Texas
$1.3M +$280K +7,151 +22%
Two Sigma Advisers
11
Two Sigma Advisers
New York
$1.26M +$23.5K +600 +2%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.23M +$228K +5,815 +18%
Goldman Sachs
13
Goldman Sachs
New York
$1.13M +$546K +13,952 +66%
Renaissance Technologies
14
Renaissance Technologies
New York
$1.08M +$878K +22,426 +203%
State Street
15
State Street
Massachusetts
$1.01M +$152K +3,880 +14%
PHP
16
Parkman Healthcare Partners
Connecticut
$896K -$35.3K -901 -3%
SCM
17
Sio Capital Management
New York
$854K – – –
CCM
18
CAAS Capital Management
New York
$670K -$1.05M -26,900 -56%
WVP
19
Worth Venture Partners
New Jersey
$550K – – –
MHS
20
M Holdings Securities
Oregon
$548K -$104K -2,660 -14%
Jacobs Levy Equity Management
21
Jacobs Levy Equity Management
New Jersey
$537K +$115K +2,927 +21%
Arrowstreet Capital
22
Arrowstreet Capital
Massachusetts
$353K +$27.7K +707 +7%
EWM
23
Essex Woodlands Management
Texas
$338K – – –
Bank of New York Mellon
24
Bank of New York Mellon
New York
$337K +$37.5K +958 +10%
N
25
Nuveen
North Carolina
$332K – – –
1
2 3 4

GYRE Hedge Fund Activity: Q3 2020 in Review

78 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2020, worth a combined $56.5M — down 31% from $81.8M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of GYRE and 9 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 33 added.

The largest buyer was Stonepine Capital Management, adding an estimated $4.51M. The largest seller was Citadel Advisors, cutting an estimated $2M.

  • 78 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2020, down from 79 in Q2 2020.
  • Funds reported $56.5M of Gyre Therapeutics stock for Q3 2020, down 31% quarter-over-quarter.
  • 9 funds opened new Gyre Therapeutics positions in Q3 2020 and 10 closed out, a net change of -1 holder.
  • The largest Gyre Therapeutics buyer in Q3 2020 was Stonepine Capital Management, an estimated $4.51M added.
  • The largest Gyre Therapeutics seller in Q3 2020 was Citadel Advisors, an estimated $2M sold.

Based on aggregated 13F filings for Q3 2020.